Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: Reversal cyclooxygenase-2 selectivity by sulfonamide group removal

Journal of Medicinal Chemistry

Volumn 47, Issue 20, 2004, Pages 4881-4890

  Di Nunno, Leonardo ^a   Vitale, Paola ^a   Scilimati, Antonio ^a   Tacconelli, Stefania ^b   Patrignani, Paola ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,6 TRIMETHYL 3 (5 METHYL 4 PHENYLISOXAZOL 3 YL)BENZENESULFONAMIDE; 2,4,6 TRIMETHYL 3 [5 METHYL 4 (4 SULFAMOYLPHENYL)ISOXAZOL 3 YL]BENZENESULFONAMIDE; 3 (2,4,6 TRIMETHOXY 3 CHLOROPHENYL) 5 METHYL 4 PHENYLISOXAZOLE; 3 (2,4,6 TRIMETHOXYPHENYL) 5 METHYL 4 PHENYLISOXAZOLE; 3 (2,4,6 TRIMETHYLPHENYL) 5 METHYL 4 PHENYLISOXAZOLE; 3 (3,5 DICHLORO 2,4,6 TRIMETHOXYPHENYL) 5 METHYL 4 PHENYLISOXAZOLE; 3 (5 CHLORO 2 FURYL) 5 METHYL 4 PHENYLISOXAZOLE; 4 [(3,5 DICHLORO 2,4,6 TRIMETHOXYPHENYL) 5 METHYLISOXAZOL 4 YL]BENZENESULFONAMIDE; 4 [3 (3 CHLORO 2,4,6 TRIMETHOXYPHENYL) 5 METHYLISOXAZOL 4 YL]BENZENESULFONAMIDE; 4 [3 (5 CHLOROFURAN 2 YL) 5 METHYLISOXAZOL 4 YL]BENZENESULFONAMIDE; 5 ETHYL 3,4 DIPHENYLISOXAZOLE; 5 METHYL 3,4 DIPHENYLISOXAZOLE; ACETONE; BENZENESULFONAMIDE DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ION; ISOXAZOLE DERIVATIVE; LITHIUM DERIVATIVE; LITHIUM DIISOPROPYLAMIDE; NITRILE; OXIDE; UNCLASSIFIED DRUG; VALDECOXIB;

ADULT; AROMATIZATION; ARTICLE; BLOOD; CONTROLLED STUDY; CYCLOADDITION; DEHYDRATION; DIPOLE; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ASSAY; FEMALE; HUMAN; IC 50; IN VITRO STUDY; MALE; NORMAL HUMAN;

ADULT; BIOCHEMISTRY; BLOOD; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; ISOXAZOLES; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; MONOCYTES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THROMBOXANE B2;

EID: 4544371096     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040782x     Document Type: Article

References (60)

1. Smith, W. L.; Langenbach, R. Why there are two cyclooxygenase isozymes. J. Clin. Invest. 2001, 12, 1491-1495.
2. Dennis, E. A. Phospholipase A2 in eicosanoid generation. Am. J. Respir. Crit. Care. Med. 2000, 161, S32-S35.
3. Marnett, L. J.; Rowlinson, S. W.; Goodwin, D. C.; Kalgutkar, A. S.; Lanzo, C. A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem. 1999, 274 (33), 22903-22906.
4. Jakobsson, P. J.; Thoren, S.; Morgenstern, R.; Samuelsson, B. Identification of the human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (13), 7220-7225.
5. Tanioka, T.; Nakatani, Y.; Semmyo, N.; Murakami, M.; Kudo, I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 2000, 275 (42), 32775-32782.
6. Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696.
7. Fitzpatrick, F. A.; Soberman, R. Regulated formation of eicosanoids. J. Clin. Invest. 2001, 107, 1347-1351.
8. Rocca, B.; Spain, L. M.; Pure, E.; Langenbach, R.; Patrono, C.; FitzGerald, G. A. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J. Clin. Invest. 1999, 103, 1469-1477.
9. Yamagata, K.; Andreasson, K. I.; Kaufmann, W. E.; Barnes, C. A.; Worley, P. F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993, 11, 371-386.
10. Kniss, D. A. Cyclooxygenases in reproductive medicine and biology. J. Soc. Gynecol. Invest. 1999, 6, 285-292.
11. Harris, R. C.; McKanna, J. A.; Akai, Y.; Jacobson, H. R.; Dubois, R. N.; Breyer, M. D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 1994, 94, 2504-2510.
12. Vio, P.; Cespedes, C.; Gallardo, P.; Masferrer, J. L. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997, 30, 687-692.
13. Ferreri, N. R.; An, S. J.; McGiff, J. C. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am. J. Physiol. 1999, 277, F360-F368.
14. Fitzgerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
15. Patrono, C.; Patrignani, P.; Garcìa Rodriguez, L. A. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 2001, 108, 7-13.
16. Clemett, D.; Goa, K. L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000, 59 (4), 957-980.
17. Matheson, A. J.; Figgitt, D. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 2001, 61 (6), 833-865.
18. Ormrod, D.; Wellington, K.; Wagstaff, A. J. Valdecoxib. Drugs 2002, 62 (14), 2059-2071.
19. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384, 644-648.
20. Walker, M. C.; Kurumbail, R. G.; Kiefer, J. R.; Moreland, K. T.; Koboldt, C. M.; Isakson, P. C.; Seibert, K.; Gierse, J. K. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 2001, 357, 709-718.
21. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis (VIGOR Study Group). N. Engl. J. Med. 2000, 343, 1520-1528.
22. Kitamura, T.; Itoh, M.; Noda, T.; Matsuura, M.; Wakabayashi, K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int. J. Cancer 2004, 109 (4), 576-580.
23. Rotondo, S.; Krauze-Brzosko, K.; Manarini, S.; Evangelista, V.; Cerletti, C. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. Eur. J. Pharmacol. 2004, 488 (1-3), 79-83.
24. Bottone, F. G., Jr; Martinez, J. M.; Alston-Mills, B.; Eling, T. E. Gene modulation by COX-1 and COX-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 2004, 25 (3), 349-357.
25. Krul, E. S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor. U.S. Patent 2003162824, 2003; CAN 139:191440, 2003.
26. Teng, X. W.; Abu-Mellal, A. K. M.; Davies, N. M. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat. J. Pharm. Pharm. Sci. 2003, 6 (2), 205-210.
27. Dooley, C. M.; Devocelle, M.; McLoughlin, B.; Nolan, K. B.; Fitzgerald, D. J.; Sharkey, C. T. A novel family of hydroxamate-based acylating inhibitors of cyclooxygenase. Mol. Pharmacol. 2003, 63 (2), 450-455.
28. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cycloxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-l-yl] benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
29. Chulada, P. C.; Thompson, M. B.; Mahler, J. F.; Doyle, C. M.; Gaul, B. W.; Lee, C.; Tiano, H. F.; Morham, S. G.; Smithies, O.; Langenbach, R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000, 60, 4705-4708
30. Tiano, H. F.; Loftin, C. D.; Akunda, J.; Lee, C. A.; Spalding, J.; Sessoms, A.; Dunson, D. B.; Rogan, E. G.; Morham, G.; Smart, R. C.; Langenbach, R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 2002, 62 (12), 3395-3401.
31. Thun, M. J.; Henley, S. J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl. Cancer Inst. 2002, 94 (4), 252-266.
32. Gupta, R. A.; Tejada, L. V.; Tong, B. J.; Das, S. K.; Morrow, J. D.; Dey, S. K.; DuBois, R. N. Cyclooxygenase-1 is Overexpressed and Promotes Angiogenic Growth Factor Production in Ovarian Cancer. Cancer Res. 2003, 63, 906-911.
33. Zhu, X.; Conklin, D.; Eisenach, J. C. Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain. Pain 2003, 104, 15-23.
34. Patrignani, P.; Panara, M. R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; Cipollone, F.; Ganci, A.; Creminon, C.; Maclouf, J.; Patrono, C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 1994, 271, 1705-1721.
35. Patrignani, P.; Filabozzi, P.; Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 1982, 69, 1366-1372.
36. Patrono, C.; Ciabattoni, G.; Pinca, E.; Pugliese, F.; Castrucci, G.; De Salvo, A.; Satta, M. A.; Peskar, B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res. 1980, 17 (3-4), 317-327.
37. Di Nunno, L.; Scilimati, A.; Vitale, P. Regioselective synthesis and side-chain metallation and elaboration of 3-aryl-5-alkyl-isoxazoles. Tetrahedron 2002, 58, 2659-2665.
38. Talley, J. J.; Brown, D.; Nagarajan, S.; Carter, J. S.; Weier, R. M.; Stealey, M. A.; Collins, P. W.; Rogers, R. S.; Seibert, K. Substituted Isoxazoles for the treatment of Inflammation. U.S. Patent 5,633,272, 1997; CAN 127:65756, 1997.
39. Dileep Kumar, J. S.; Ho, M. M.; Leung, J. M.; Toyokuni, T. Convenient Approach to 3,4-Diarylisoxazoles Based on the Suzuki Cross-Coupling Reaction. Adv. Synth. Catal. 2002, 344, 1146-1151.
40. Escale, R.; Petrus, F.; Verducci, J. Synthèse et caractérisation d'hydroxy-5-isoxazolines-2 (Synthesis and characterization of hydroxy-5-isoxazolines-2). Bull. Soc. Chim. Fr. 1974, 3-4 (part 2), 725-733.
41. Di Nunno, L.; Scilimati, A. Synthesis of 3-aryl-4,5-dihydro-5-hydroxy-1, 2-oxazoles by reaction of substituted benzonitrile oxides with the enolate ion of acetaldehyde. Tetrahedron 1987, 43, 2181-2189.
42. Sorbera, L. A.; Leeson, P. A.; Castañer, J.; Castañer, R. N. Valdecoxib and Parecoxib Sodium. Drugs Future 2001, 26, 133-140.
43. van Albada, M. P.; Cerfontain, H. Aromatic Sulphonation. Part 60. Sulphonation in the Reaction of Aromatic Compounds with Chlorosulphuric Acid in Nitromethane and in Dichloromethane. J. Chem. Soc., Perkin Trans. 2 1977, 1548-1557.
44. van Albada, M. P.; Cerfontain, H. Aromatic Sulphonation. Part 61. Sulphonylation in the Reaction of Aromatic Compounds with Chlorosulphuric Acid in Nitromethane and in Dichloromethane. J. Chem. Soc., Perkin Trans. 2 1977, 1557-1559.
45. Smith, M. B.; March, J. Effects of Structure on Reactivity. In March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th ed.; A Wiley-Interscience Publication, John Wiley & Sons: New York, 2001; pp 374-375.
46. Bellec, C.; Bertin, D.; Colau, R.; Deswarte, S.; Maitte, P.; Viel, C. Préparation d'isoxazoles trisubstitués par réduction chimique et électrochimique d'α-acyl β-nitrostilbènes (Preparation of trisubstituted isoxazoles by chemical and electrochemical reduction of a-acyl-β-nitrostilbenes). J. Heterocycl. Chem. 1979,16 (8), 1657-1759.
47. Letendre, L. J.; Kunda, S. A.; Gallagher, D. J.; Seaney, L. M. Method for preparing valdecoxib and related benzenesulfonyl compounds. PCT Int. Appl. WO 2003029230, 2003; CAN 138: 304268, 2003.
48. Ethyl-3,4-diphenylisoxazole was synthesized as reported in the Experimental Section. See also the following: Scilimati, A.; Di Nunno, L.; Vitale, P.; Patrignani, P.; Tacconelli, S. Italian Patent MI2004A000019, 2004.
49. Tacconelli, S.; Capone, M. L.; Sciulli, M. G.; Ricciotti, E.; Patrignani, P. The selectivity of novel COX-2 inhibitors in human whole blood assays of COX-isozyme activity. Curr. Med. Res., Opin. 2002, 18 (8), 503-511.
50. Hood, W. F.; Gierse, J. K.; Isakson, P. C.; Kiefer, J. R.; Kurumbail, R. G.; Seibert, K.; Monahan, J. B. Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol. Pharmacol. 2003, 63, 870-877.
51. Chandrasekharan, N. V.; Dai, H.; Roos, L. T.; Evanson, N. K.; Tomsik, J.; Elton, S. T.; Simmons, D. L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13926-13931.
52. Schwab, J. M.; Schluesener, J.; Laufer, S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003, 361, 981-982.
53. Schwab, J. M.; Beiter, T.; Linder, J. U.; Laufer, S.; Schulz, J. E.; Meyermann, R.; Schluesener, H. J. COX-3: a virtual pain target in humans? FASEB J. 2003, 17 (15), 2174-2175.
54. Warner, T. D.; Mitchell, J. A. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13371-13373.
55. McAdam, B. F.; Mardini, I. A.; Habib, A.; Burke, A.; Lawson, J. A.; Kapoor, S.; FitzGerald, G. A. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest 2000, 105 (10), 1473-1482.
56. Suffert, J. Simple Direct Titration of Organolithium Reagents Using N-Pivaloyl-o-toluidine and/or N-Pivaloyl-o-benzylaniline. J. Org. Chem. 1989, 54, 509-510.
57. 4). Tetrahedron 2000, 56, 1057-1064.
58. Lloyd, G.; Whalley, W. B.; Travers, R. B. Some Chlorinated Derivatives of Phloroglucinol. J. Chem. Soc. 1956, 3209-3212.
59. Davies, M. W.; Wybrow, R. A. J.; Johnson, C. N.; Harrity, J. P. A. A regioselective cycloaddition route to isoxazoleboronic esters. Chem. Commun. 2001, 1558-1559.
60. Ciabattoni, G.; Pugliese, F.; Spaldi, M.; Cinotti, G. A.; Patrono, C. Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine. J. Endocrinol. Invest. 1979, 2 (2), 173-182.